Literature DB >> 24754873

Postoperative hemorrhage in an elderly patient with a glioblastoma multiform and a calcified chronic subdural hematoma.

Jun Cai, Yanting Zhang, Xiaoxin Bai, Shaoxue Li, Jinhua Chen, Ruicong Chen, Hao Lin, Shengping Huang1.   

Abstract

BACKGROUND: Cases with brain tumor and subdural hematoma are rare; surgical management of the elderly patients with a glioblastoma multiform (GBM) and a chronic subdural hematoma (CSDH) can be intractable. CASE DESCRIPTION: We report a 77-year-old patient, who had a left front lobe GBM and a giant, calcified, left frontoparietaloccipitotemporal CSDH. The patient recovered well from anesthesia after removal of the GBM and CSDH. However, the patient developed severe hemiplegia and aphasia because of the in-situ hemorrhage 1 day later. Laboratory tests indicated disseminated intravascular coagulation (DIC) leading to the postoperative hemorrhage. The patient was left with hemiparesis and alalia after the in-situ hematoma evacuation.
CONCLUSIONS: We presume elderly patients have a higher incidence of postoperative hemorrhage in residual intracranial cavity owing to higher possibility to get DIC. A less aggressive surgical management could be a more appropriate choice.

Entities:  

Mesh:

Year:  2014        PMID: 24754873      PMCID: PMC4005469          DOI: 10.1186/1477-7819-12-110

Source DB:  PubMed          Journal:  World J Surg Oncol        ISSN: 1477-7819            Impact factor:   2.754


Background

Brain tumors and subdural hematomas are the most common intracranial lesions suffered by the elderly [1]. However, cases with both these two devastating maladies are infrequent. In addition, there are few data on the complications of management of elderly patients with brain tumors and chronic subdural hematomas. The surgical management of these cases can be problematic.

Case presentation

A 77-year-old Chinese man was admitted to our hospital with a history of 2 weeks of hypomnesis and mental deterioration. Physical examination was unremarkable. He was diagnosed by computed tomography (CT) and magnetic resonance imaging (MRI) with a glioblastoma multiform (GBM) located in the left front lobe as well as a chronic subdural hematoma (CSDH) located in the left frontoparietaloccipitotemporal intracranial cavity (Figure 1a-d). A specific craniotomy was performed; the GBM was resected followed by evacuation of the giant and calcified CSDH (Figure 2a-d). The patient recoverexd from anesthesia well and no new neurological deficit was found after resuscitation. The next morning, the patient developed severe hemiplegia and aphasia due to the in-situ hemorrhage (Figure 1e-f). Postoperative laboratory work-up revealed there was a reduction of fibrinogen (0.69 g/L; normal: 2-4 g/L) and a huge increase of d-dimers (29,750 μg/L; normal: 0-500 μg/L), with platelet count, prothrombin time, and activated partial thromboplastin time all within normal limits. After correction of coagulopathy, secondary craniotomy was performed for the intracranial hematomas evacuation. The patient was left with hemiparesis and alalia after the second operation (Figure 1g-h) and discharged to take extensive neurological rehabilitation.
Figure 1

The preoperative and postoperative images of CT and MRI. (a,b) The CT images display the CSDH. The arrowheads point to the calcified membranes. (c, d) The MRI images show the GBM (G) and the CSDH (H). (e, f) The CT images indicate the in-situ hemorrhages after removal of the GBM and CSDH. (g, h)The postoperative CT images of the secondary craniotomy.

Figure 2

The photographs of the CSDH. (a) The panel displays the intact CSDH. (b) The panel indicates the isolated CSDH. (c) The panel shows the dural surface of the CSDH. Arrowheads point to the inner contents. (d) The panel shows the cortical surface of the CSDH.

The preoperative and postoperative images of CT and MRI. (a,b) The CT images display the CSDH. The arrowheads point to the calcified membranes. (c, d) The MRI images show the GBM (G) and the CSDH (H). (e, f) The CT images indicate the in-situ hemorrhages after removal of the GBM and CSDH. (g, h)The postoperative CT images of the secondary craniotomy. The photographs of the CSDH. (a) The panel displays the intact CSDH. (b) The panel indicates the isolated CSDH. (c) The panel shows the dural surface of the CSDH. Arrowheads point to the inner contents. (d) The panel shows the cortical surface of the CSDH.

Discussion

GBM is the most common primary malignant brain tumor in geriatric population [1]. Maximal surgical resection is one of the standard treatments for GBM [2]. Craniotomy remains the best option for evacuation of calcified CSDH [3]. Concerning this case, after GBM resection, we expanded the bone flap to thoroughly evacuate the calcified CSDH. No bleeding was found after the surgical procedures. However, the in-situ hemorrhage was detected 1 day later. Postoperative laboratory analysis indicated the patient was in a state of prior disseminated intravascular coagulation (DIC) at that time. A diagnosis of DIC can be established if laboratory test results show a decreased fibrinogen and increased fibrin degradation products, such as d-dimers [4]. A number of cases are reported that DIC developed during or after removal of brain tumors [5-9], especially in the elderly. Development of DIC during or after craniotomy for brain tumor resection constitutes a very severe complication because nearly half of the patients in the reported cases died postoperatively [9]. There are four subtypes of GBM distinguished by gene expression patterns and clinical characteristics [10]. Studying GBMs using this new subtype classification therefore may accelerate our understanding of GBM pathology. A large sample set might help to determine whether the postoperative DIC correlate with the GBM subtypes, which can be used for optimal therapy.

Conclusion

In summary, we presume elderly patients have a higher incidence of postoperative hemorrhage in residual intracranial cavity owing to higher possibility to get DIC. In the present case, a discreet two-step surgery which is comprised of resection of the GBM and evacuation of the giant and calcified CSDH could be more appropriate.

Consent

Written informed consent was obtained from the patient and his daughter for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Abbreviations

CSDH: Chronic subdural hematoma; CT: Computed tomography; DIC: Disseminated intravascular coagulation; GBM: Glioblastoma multiform; MRI: Magnetic resonance imaging.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

JC took a part in the surgical and medical management of the patient, and drafted the manuscript. YZ took a part in the medical management of the case and assisted in preparation of the manuscript. XB took a part in the first craniotomy and revised the manuscript. SL and JC participated in the second operation. RC and HL participated in the rehabilitation of the patient. SH supervised the whole management of the patient and took a part in the second craniotomy. All authors read and approved the final manuscript.

Authors’ information

JC, XB, SL, JC, and SH are neurosurgeons. YZ, who specializes in intensive care therapy, is a neurologist. RC and HL are physical therapists.
  10 in total

1.  Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation.

Authors:  F B Taylor; C H Toh; W K Hoots; H Wada; M Levi
Journal:  Thromb Haemost       Date:  2001-11       Impact factor: 5.249

2.  Organized chronic subdural hematoma requiring craniotomy--five case reports.

Authors:  S Imaizumi; T Onuma; M Kameyama; H Naganuma
Journal:  Neurol Med Chir (Tokyo)       Date:  2001-01       Impact factor: 1.742

3.  Disseminated intravascular coagulation complicating resection of a malignant meningioma.

Authors:  J E Brecknell; C A McLean; H Hirano; G M Malham
Journal:  Br J Neurosurg       Date:  2006-08       Impact factor: 1.596

Review 4.  Neurosurgery in the elderly: brain tumors and subdural hematomas.

Authors:  Eric P Roger; John Butler; Edward C Benzel
Journal:  Clin Geriatr Med       Date:  2006-08       Impact factor: 3.076

5.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.

Authors:  Roel G W Verhaak; Katherine A Hoadley; Elizabeth Purdom; Victoria Wang; Yuan Qi; Matthew D Wilkerson; C Ryan Miller; Li Ding; Todd Golub; Jill P Mesirov; Gabriele Alexe; Michael Lawrence; Michael O'Kelly; Pablo Tamayo; Barbara A Weir; Stacey Gabriel; Wendy Winckler; Supriya Gupta; Lakshmi Jakkula; Heidi S Feiler; J Graeme Hodgson; C David James; Jann N Sarkaria; Cameron Brennan; Ari Kahn; Paul T Spellman; Richard K Wilson; Terence P Speed; Joe W Gray; Matthew Meyerson; Gad Getz; Charles M Perou; D Neil Hayes
Journal:  Cancer Cell       Date:  2010-01-19       Impact factor: 31.743

Review 6.  Disseminated intravascular coagulation during resection of a meningioma: case report.

Authors:  Ana M Velez; William A Friedman
Journal:  Neurosurgery       Date:  2011-04       Impact factor: 4.654

7.  Melanotic meningioma complicated by disseminated intravascular coagulation.

Authors:  J R Portugal; A Alencar; L C Brito Lira; P Carvalho
Journal:  Surg Neurol       Date:  1984-03

8.  Life-threatening hemorrhagic diathesis due to disseminated intravascular coagulation during elective brain tumor surgery.

Authors:  M M Berger; P Ravussin; G Vielle; H Fankhauser
Journal:  J Neurosurg Anesthesiol       Date:  1995-01       Impact factor: 3.956

Review 9.  Glioblastoma multiforme: overview of current treatment and future perspectives.

Authors:  Kevin Anton; Joachim M Baehring; Tina Mayer
Journal:  Hematol Oncol Clin North Am       Date:  2012-05-11       Impact factor: 3.722

10.  Hyperfibrinolysis during intracranial surgery: effect of high dose aprotinin.

Authors:  J D Palmer; D A Francis; O S Roath; J L Francis; F Iannotti
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-01       Impact factor: 10.154

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.